Shunsuke Nakazawa
Dainippon Sumitomo Pharma Co., Ltd.
PsychologyReceptorLurasidoneDopamine receptor D2Partial agonist
What is this?
Publications 2
#1Shunsuke NakazawaH-Index: 2
#2Takeshi MuraiH-Index: 5
Last. Kazuhito IkedaH-Index: 6
view all 5 authors...
Rationale Growing evidence suggests that dopamine D4 receptors (D4Rs) are involved in controlling executive functions. We have previously demonstrated that Ro 10-5824, a D4R partial agonist, improves the performance of common marmosets in the object retrieval detour (ORD) task. However, the neural mechanisms underlying this improvement are unknown.
3 CitationsSource
#1Shunsuke Nakazawa (Dainippon Sumitomo Pharma Co., Ltd.)H-Index: 2
#2Chihiro YokoyamaH-Index: 12
Last. Hirotaka OnoeH-Index: 27
view all 8 authors...
Rationale Lurasidone is a novel antipsychotic drug with potent binding affinity for dopamine D2 and serotonin (5-hydroxytryptamine, 5-HT)2A, 5-HT7, and 5-HT1A receptors. Previous pharmacological studies have revealed that lurasidone exhibits a preferable profile (potent antipsychotic activity and lower incidence of catalepsy) to other antipsychotic drugs, although the contribution of receptor subtypes to this profile remains unclear.
11 CitationsSource